Soleno Therapeutics, Inc. (SLNO)
After hours:
| Previous close | 0.1794 |
| Open | 0.1887 |
| Bid | 0.1800 x 1000 |
| Ask | 0.1880 x 3200 |
| Day's range | 0.1700 - 0.1940 |
| 52-week range | 0.1300 - 1.6700 |
| Volume | |
| Avg. volume | 779,179 |
| Market cap | 22.096M |
| Beta (5Y monthly) | 0.41 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3470 |
| Earnings date | 26 July 2022 - 01 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.00 |
- GlobeNewswire
Soleno Therapeutics Announces Presentations at the 2022 European Congress of Endocrinology
REDWOOD CITY, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced presentations at the upcoming 2022 European Congress of Endocrinology (ECE), which is being held May 21-24, 2022, in Milan, Italy. Details of the presentations are as follows: 2022 European Congress of Endocrinology (ECE) Title:DCCR UpdateFormat:Presentation at the I
- Zacks
KemPharm (KMPH) Stock Up on Deal to Acquire Orphazyme for $12.8M
KemPharm (KMPH) inks deal to acquire Orphazyme A/S, which will add to its portfolio the latter's pipeline candidate, arimoclomol, being developed for treating Niemann-Pick disease type C. Shares rise.
- GlobeNewswire
Soleno Therapeutics to Participate in the H.C. Wainwright Global Investment Conference
REDWOOD CITY, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Global Investment Conference, being held May 23-26, 2022, virtually and in Miami, FL. The presentation will be available on-demand beginning at 7 AM Eastern
